Literature DB >> 3524282

Cutaneous follicular lymphoma.

C F Garcia, L M Weiss, R A Warnke, G S Wood.   

Abstract

Fifteen cases of cutaneous follicular lymphoma were evaluated clinically, histologically, and immunologically. Nine of the patients presented with skin disease alone, which showed a predilection for the scalp and forehead. The six remaining cases had either concurrent or secondary cutaneous involvement. All of the cases had a nodular configuration which was evident histologically or immunologically. In many cases, the diagnostic microscopic fields were in the deep dermis or subcutis, with nonspecific inflammation in the superficial dermis. The cases consisted of five small cleaved, seven mixed, and three large cell follicular lymphomas. A senior dermatopathologist diagnosed four of the 15 cases as benign, indicating the difficulty of diagnosis by morphology alone when the biopsy is small or the inflammatory component is prominent. This underscores the importance of large, deep biopsies for accurate histologic diagnosis. Immunological studies confirmed the B cell lineage of these lesions. An unexpectedly high proportion of immunoglobulin-negative cases (eight cases) was found, especially among the primary cutaneous follicular lymphomas (six of nine cases). Immunoglobulin-expressing cases exhibited monotypic immunoglobulin light-chain staining of tumor cells. In all cases, the dendritic reticulum cell network within lymphoma follicles lacked the polytypic immunoglobulin complexes characteristic of reactive follicles. As described previously for follicular lymphomas in lymph nodes, many cases exhibited polytypic follicular mantle zones similar to reactive follicles. The low-grade nature of these lymphomas was supported by clinical follow-up. We conclude that given adequate sampling, cutaneous follicular lymphomas can usually be diagnosed by histologic criteria similar to those used for lymph nodes; however, immunohistologic studies are an important adjunct.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524282     DOI: 10.1097/00000478-198607000-00002

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  In situ localization of HuHF serine protease mRNA and cytotoxic cell-associated antigens in human dermatoses. A novel method for the detection of cytotoxic cells in human tissues.

Authors:  G S Wood; C Mueller; R A Warnke; I L Weissman
Journal:  Am J Pathol       Date:  1988-11       Impact factor: 4.307

2.  Large cell lymphocytoma: follow-up, immunopathology studies, and comparison to cutaneous follicular and Crosti lymphoma.

Authors:  R K Winkelmann; K Dabski
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

3.  Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea.

Authors:  Moon Jin Kim; Min Eui Hong; Chi Hoon Maeng; Hyun Ae Jung; Jung Yong Hong; Moon Ki Choi; Seok Jin Kim; Young Hyeh Ko; Won Seog Kim
Journal:  Int J Hematol       Date:  2015-01-01       Impact factor: 2.490

4.  Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University.

Authors:  Brad Haverkos; Kelly Tyler; Alejandro A Gru; Francisca Kartono Winardi; Julie Frederickson; Justin Hastings; Camille Elkins; Xiaoli Zhang; Meng Xu-Welliver; Henry K Wong; Pierluigi Porcu
Journal:  Oncologist       Date:  2015-08-25

5.  Clonal rearrangements of immunoglobulin genes and progression to B cell lymphoma in cutaneous lymphoid hyperplasia.

Authors:  G S Wood; B Y Ngan; R Tung; T E Hoffman; E A Abel; R T Hoppe; R A Warnke; M L Cleary; J Sklar
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

Review 6.  Radiotherapy of primary cutaneous follicle center lymphoma: case report and review of literature.

Authors:  Romana Ceovic; Ivana Jovanovic; Kresimir Kostovic; Jaka Rados; Snjezana Dotlic; Ivo Radman; Sandra Marinovic Kulisic; Davorin Loncaric
Journal:  Radiat Oncol       Date:  2013-06-20       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.